| Recruiting | Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors Solid Cancers | Phase 2 | 2027-08-31 |
| Recruiting | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Ca Bladder Cancer, Liquid Biopsy, Immunotherapy | Phase 2 | 2026-03-16 |
| Recruiting | Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy | — | 2026-03-01 |
| Recruiting | Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Upper Tract Urothelial Carcinoma, Lymph Node Dissection | N/A | 2026-01-01 |
| Not Yet Recruiting | Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RC Renal Cell Carcinoma (Kidney Cancer) | N/A | 2026-01-01 |
| Recruiting | Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor | Phase 2 | 2025-11-25 |
| Not Yet Recruiting | Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Urolithiasis, Renal Stones | N/A | 2025-10-01 |
| Recruiting | Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Ca Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor | N/A | 2025-09-28 |
| Recruiting | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cance Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation | Phase 2 | 2025-09-22 |
| Recruiting | Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Blad Bladder Cancer, Liquid Biopsy, Cystoscopy | N/A | 2025-09-20 |
| Recruiting | The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of Hig Bladder Cancer, Liquid Biopsy | — | 2025-09-01 |
| Recruiting | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Ad Renal Cell Carcinoma (RCC) | Phase 2 | 2025-07-31 |
| Recruiting | Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor | Phase 2 | 2025-07-05 |
| Recruiting | Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor | Phase 2 | 2025-07-05 |
| Recruiting | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4 Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine | Phase 1 / Phase 2 | 2024-11-27 |
| Recruiting | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion Solid Tumor, Precision Medicine | Phase 2 | 2024-11-01 |
| Recruiting | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure Prostate Cancer, CDK12 Gene Mutation | Phase 1 / Phase 2 | 2024-09-24 |
| Recruiting | Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral M Prostate Cancer, Organoid | — | 2024-06-01 |
| Recruiting | Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesotheli Malignant Pleural Mesothelioma, Advanced | — | 2023-07-20 |
| Unknown | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification | Phase 2 | 2023-05-01 |
| Completed | Study on the Influencing Factors of Electroencephalogram Parameters Under Anesthesia EEC | Phase 4 | 2023-03-01 |
| Recruiting | Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-posi Neoadjuvant Immunotherapy | Phase 2 | 2022-12-30 |
| Unknown | Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors Solid Tumor, EGFR Amplification | N/A | 2022-12-01 |
| Active Not Recruiting | A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer High-risk Renal Cell Carcinoma | Phase 2 | 2022-10-10 |
| Unknown | Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer Bladder Cancer | Phase 2 | 2022-10-10 |
| Unknown | DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors Solid Tumor, Individuation | — | 2022-08-07 |
| Unknown | Tislelizumab Plus Lenvatinib in Stage III-IV RCC Advanced Kidney Cancer | Phase 2 | 2022-07-01 |
| Completed | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC Renal Cell Carcinoma | Phase 2 | 2022-07-01 |
| Unknown | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma Bladder Urothelial Carcinoma | Phase 4 | 2022-01-05 |
| Unknown | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | 2021-12-27 |
| Unknown | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multi Muscle Invasive Bladder Cancer Urothelial Carcinoma | Phase 2 | 2021-11-11 |
| Unknown | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms | Phase 2 | 2021-10-01 |
| Unknown | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Ca Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | 2021-08-20 |
| Unknown | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | 2021-08-01 |
| Unknown | Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | 2021-07-23 |
| Unknown | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | 2020-12-27 |
| Unknown | MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors Refractory Solid Tumors, Next Generation Sequencing | — | 2020-12-01 |
| Unknown | Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer Oligometastasis, Lung Neoplasms | Phase 2 | 2020-09-01 |
| Unknown | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | 2020-07-11 |
| Unknown | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small C Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | 2020-07-01 |
| Unknown | The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor Solid Tumor, HER2 Gene Mutation, HER-2 Gene Amplification | Phase 2 | 2019-12-01 |
| Unknown | Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer Muscle Invasive Bladder Cancer | Phase 2 | 2019-09-17 |
| Unknown | Treatment of Carrying TP53 Harmful Mutations Advanced Cancer | Phase 1 | 2019-07-01 |
| Unknown | Personalized Mini-PDX for Metastatic CRPC Prostate Cancer | N/A | 2019-01-28 |
| Unknown | Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficienc Prostate Cancer | Phase 3 | 2019-01-01 |
| Unknown | Selective Treatment According to Molecular Subtype of Prostate Cancer Castration-resistant Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | 2018-08-01 |
| Unknown | Advanced Refractory Solid Tumors With TP53 Mutations Register Study Solid Tumor, Adult | — | 2018-08-01 |
| Active Not Recruiting | Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes Renal Tumors | — | 2018-01-01 |
| Unknown | Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing Solid Tumor, Adult | — | 2017-06-01 |
| Completed | Tissue Predictors of Abiraterone Benefit Metastatic Castration-resistant Prostate Cancer | — | 2017-05-05 |
| Unknown | Predictive Nomogram of CRPC Castration-resistant Prostate Cancer, Metastatic Cancer | — | 2017-05-04 |